Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 6873281, 14 pages
https://doi.org/10.1155/2017/6873281
Research Article

Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis

1Division of Brain Science, Department of Physiology, Kurume University School of Medicine, Kurume, Japan
2Department of Neurosurgery, Kurume University School of Medicine, Kurume, Japan
3Department of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan
4Department of Pharmacology, Faculty of Dentistry, Mahidol University, Bangkok, Thailand
5Division of Laboratory Animal Science, Natural Science Center for Research and Education, Kagoshima University, Kagoshima, Japan
6Department of Biomedical Engineering, Laboratory of Functional Foods, Osaka Institute of Technology, Osaka, Japan
7Research Institute, Fujimori Kogyo Co., Yokohama, Kanagawa, Japan
8Course of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
9Department of Veterinary Science, Laboratory of Diagnostic Imaging, Faculty of Agriculture, Kagoshima University, Kagoshima, Japan
10Department of Restorative Dentistry and Endodontology, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan
11Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan
12School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
13Department of Emergency and Critical Care Medicine, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan

Correspondence should be addressed to Takashi Ito; pj.ca.u-amihsogak.mfuk.3m@ihsakat and Ikuro Maruyama; pj.ca.u-amihsogak.mfuk.2m@amayuram

Received 7 July 2017; Accepted 7 September 2017; Published 10 November 2017

Academic Editor: Adrian Doroszko

Copyright © 2017 Kiyoshi Kikuchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Kikuchi, E. Tanaka, Y. Murai, and S. Tancharoen, “Clinical trials in acute ischemic stroke,” CNS Drugs, vol. 28, no. 10, pp. 929–938, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Gravanis and S. E. Tsirka, “Tissue-type plasminogen activator as a therapeutic target in stroke,” Expert Opinion on Therapeutic Targets, vol. 12, no. 2, pp. 159–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Kamogawa and Y. Sueishi, “A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 5, pp. 1376–1379, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Kikuchi, K.-i. Kawahara, N. Miyagi et al., “Edaravone: a new therapeutic approach for the treatment of acute stroke,” Medical Hypotheses, vol. 75, no. 6, pp. 583–585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Kikuchi, K. Kawahara, S. Tancharoen et al., “The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 3, pp. 865–874, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Kikuchi, N. Takeshige, N. Miura et al., “Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases (review),” Experimental and Therapeutic Medicine, vol. 3, no. 1, pp. 3–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Kikuchi, S. Tancharoen, F. Matsuda et al., “Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4,” Biochemical and Biophysical Research Communications, vol. 390, no. 4, pp. 1121–1125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Kikuchi, H. Uchikado, M. Morioka, Y. Murai, and E. Tanaka, “Clinical neuroprotective drugs for treatment and prevention of stroke,” International Journal of Molecular Sciences, vol. 13, no. 6, pp. 7739–7761, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Tanaka, S. Niiyama, S. Sato, A. Yamada, and H. Higashi, “Arachidonic acid metabolites contribute to the irreversible depolarization induced by in vitro ischemia,” Journal of Neurophysiology, vol. 90, no. 5, pp. 3213–3223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Wada, H. Yasunaga, R. Inokuchi et al., “Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator,” Journal of the Neurological Sciences, vol. 345, no. 1-2, pp. 106–111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kono, K. Deguchi, N. Morimoto et al., “Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan,” Journal of Stroke & Cerebrovascular Diseases, vol. 22, no. 3, pp. 190–196, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Kono, K. Deguchi, N. Morimoto et al., “Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age,” Journal of Stroke & Cerebrovascular Diseases, vol. 22, no. 7, pp. 1175–1183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Miyaji, S. Yoshimura, N. Sakai et al., “Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry,” Neurologia Medico-Chirurgica, vol. 55, no. 3, pp. 241–247, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kimura, J. Aoki, Y. Sakamoto et al., “Administration of edaravone, a free radical scavenger, during t-pa infusion can enhance early recanalization in acute stroke patients—a preliminary study,” Journal of the Neurological Sciences, vol. 313, no. 1-2, pp. 132–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Emeis, “Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products,” Annals of the New York Academy of Sciences, vol. 667, pp. 249–258, 1992. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Aoki, K. Kimura, N. Morita et al., “YAMATO Study (tissue-type plasminogen activator and edaravone combination therapy),” Stroke, vol. 48, no. 3, pp. 712–719, 2017. View at Publisher · View at Google Scholar
  17. K. Yagi, K. T. Kitazato, M. Uno et al., “Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator,” Stroke, vol. 40, no. 3, pp. 626–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Yamashita, T. Kamiya, K. Deguchi et al., “Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain,” Journal of Cerebral Blood Flow & Metabolism, vol. 29, no. 4, pp. 715–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Yamashita, T. Sato, K. Sakamoto, H. Ishii, and J. Yamamoto, “The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model,” Thrombosis Research, vol. 135, no. 6, pp. 1209–1213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Yamashita, M. Shoge, E. Oda et al., “The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo,” Platelets, vol. 17, no. 3, pp. 201–206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Sakamoto, T. Yamashita, H. Yamanishi, and J. Yamamoto, “The effect of edaravone to leukocyte rolling and adhesion molecule expression in microvessels,” Health, vol. 5, no. 3, pp. 402–408, 2013. View at Publisher · View at Google Scholar
  22. A. O. Spiel, F. B. Mayr, C. Firbas, P. Quehenberger, and B. Jilma, “Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans,” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 411–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Traby, M. Kollars, L. Eischer, S. Eichinger, and P. A. Kyrle, “Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study,” PLoS One, vol. 7, no. 12, article e51447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Hosokawa, T. Ohnishi, T. Kondo et al., “A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions,” Journal of Thrombosis and Haemostasis, vol. 9, no. 10, pp. 2029–2037, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Shimamura, N. Matsuda, and K. Kakuta, “A model of rat embolic cerebral infarction with a quantifiable, autologous arterial blood clot,” Translational Stroke Research, vol. 4, no. 5, pp. 564–570, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Otsuka, H. Sakakima, M. Sumizono, S. Takada, T. Terashi, and Y. Yoshida, “The neuroprotective effects of preconditioning exercise on brain damage and neurotrophic factors after focal brain ischemia in rats,” Behavioural Brain Research, vol. 303, pp. 9–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Kikuchi, S. Tancharoen, N. Takeshige et al., “The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13909–13930, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Lukic-Panin, K. Deguchi, T. Yamashita et al., “Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage,” Current Neurovascular Research, vol. 7, no. 4, pp. 319–329, 2010. View at Publisher · View at Google Scholar
  29. T. Watanabe, M. Tanaka, K. Watanabe, Y. Takamatsu, and A. Tobe, “Research and development of the free radical scavenger edaravone as a neuroprotectant,” Yakugaku Zasshi–Journal of the Pharmaceutical Society of Japan, vol. 124, no. 3, pp. 99–111, 2004, (in Japanese). View at Publisher · View at Google Scholar
  30. V. J. Marder, A. Blinc, T. Gruber et al., “Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke,” Stroke, vol. 42, no. 8, pp. 2222–2228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Janiszewski, A. O. Do Carmo, M. A. Pedro, E. Silva, E. Knobel, and F. R. Laurindo, “Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway,” Critical Care Medicine, vol. 32, no. 3, pp. 818–825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Cao, D. A. Lawrence, Y. Li et al., “Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration,” EMBO Journal, vol. 25, no. 9, pp. 1860–1870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Mishina, Y. Komaba, S. Kobayashi et al., “Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism,” Neurologia Medico-Chirurgica, vol. 48, no. 7, pp. 292–297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. H. Feng and G. Hart, “In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions,” Cardiovascular Research, vol. 30, no. 2, pp. 255–261, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Kaste, S. Murayama, G. A. Ford, D. W. J. Dippel, M. R. Walters, and T. Tatlisumak, “Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen,” Cerebrovascular Diseases, vol. 36, no. 3, pp. 196–204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Hardiman and L. H. van den Berg, “Edaravone: a new treatment for ALS on the horizon?” The Lancet Neurology, vol. 16, no. 7, pp. 490-491, 2017. View at Publisher · View at Google Scholar
  37. Edaravone (MCI-186) ALS 19 Study Group, “Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial,” The Lancet Neurology, vol. 16, no. 7, pp. 505–512, 2017. View at Publisher · View at Google Scholar